RMD RESMED INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 943819 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.0%
TTM net income YoY10.8%
TTM EPS YoY12.4%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR20.7%
Margins
Gross margin61.1%
Operating margin33.0%
Net margin27.8%
FCF margin28.1%
EBITDA margin36.4%
Returns
ROE26.4%
ROA19.3%
ROIC (approx.)27.9%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets27.6%
Debt / equity0.07x
Current ratio2.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio-2.2%
Payout ratio22.4%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.41B | $1.46B | $1.43B | $1.42B | $1.34B | $1.35B | $1.29B | $1.28B |
| Cost of revenue | $544.25M | $602.43M | $540.43M | $544.08M | $517.92M | $527.92M | $525.33M | $530.81M |
| Gross profit | $870.57M | $861.22M | $890.98M | $878.72M | $817.66M | $820.07M | $766.41M | $751.27M |
| R&D expense | $102.86M | $105.72M | $94.27M | $90.97M | $89.48M | $86.44M | $83.94M | $81.37M |
| SG&A expense | $314.72M | $296.28M | $285.65M | $278.40M | $281.65M | $265.12M | $245.30M | $241.61M |
| Operating income | $452.98M | $448.71M | $499.81M | $491.66M | $446.54M | $454.54M | $426.27M | $417.24M |
| Interest expense | $4.81M | — | — | — | $7.12M | — | — | — |
| Pretax income | $539.15M | $474.16M | $502.31M | $496.15M | $446.79M | $458.05M | $417.69M | $418.32M |
| Income tax | $120.74M | $90.73M | $103.58M | $103.56M | $98.26M | $78.35M | $52.65M | $73.70M |
| Net income | $418.41M | $383.43M | $398.73M | $392.59M | $348.54M | $379.70M | $365.04M | $344.62M |
| EBITDA | $494.73M | $493.49M | $558.79M | $541.54M | $494.24M | $518.17M | $469.94M | $463.68M |
| EPS (basic) | 2.93 | — | 2.74 | 2.69 | 2.38 | — | 2.49 | 2.35 |
| EPS (diluted) | 2.92 | — | 2.74 | 2.68 | 2.37 | — | 2.48 | 2.34 |
| Dividends declared per share | 0.66 | 0.60 | 0.60 | 0.60 | 0.60 | 0.53 | 0.53 | 0.53 |
| Weighted avg. shares (diluted) | 143.41M | — | 145.72M | 146.37M | 146.90M | — | 147.22M | 147.48M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.01B | $1.47B | $1.66B | $1.42B | $1.38B | $1.21B | $932.71M | $521.94M |
| Receivables | $972.50M | $1.04B | $998.84M | $985.63M | $907.27M | $939.49M | $907.83M | $859.94M |
| Inventory | $1.02B | $945.80M | $911.88M | $922.04M | $945.81M | $927.71M | $862.64M | $882.10M |
| Current assets | $3.51B | $4.32B | $4.06B | $3.82B | $3.63B | $3.51B | $3.21B | $2.84B |
| PP&E, net | $601.79M | $581.83M | $566.97M | $564.25M | $563.63M | $550.79M | $535.34M | $520.16M |
| Goodwill | $2.91B | $2.91B | $3.04B | $3.04B | $3.04B | $3.05B | $2.85B | $2.81B |
| Intangibles | $442.68M | $452.74M | $425.19M | $430.24M | $447.07M | $464.86M | $430.11M | $438.00M |
| Total assets | $8.21B | $8.97B | $8.78B | $8.50B | $8.31B | $8.17B | $7.57B | $7.14B |
| Current liabilities | $1.32B | $1.40B | $1.35B | $1.25B | $1.26B | $1.02B | $940.52M | $851.96M |
| Short-term debt | $159.97M | $259.95M | $259.93M | $259.91M | $259.90M | $9.90M | $9.91M | $9.91M |
| Long-term debt | $249.63M | $399.42M | $404.17M | $403.92M | $408.66M | $658.39M | $663.13M | $662.86M |
| Total debt | $409.60M | $659.37M | $664.10M | $663.83M | $668.56M | $668.29M | $673.03M | $672.76M |
| Total liabilities | $2.26B | $2.38B | $2.29B | $2.18B | $2.19B | $2.21B | $2.02B | $1.89B |
| Shareholders' equity | $5.95B | $6.59B | $6.49B | $6.32B | $6.12B | $5.97B | $5.55B | $5.25B |
| Net debt | -$601.14M | -$809.87M | -$996.42M | -$753.24M | -$715.29M | -$541.16M | -$259.68M | $150.82M |
| Shares outstanding | 140.64M | 144.24M | 145.04M | 145.66M | 145.94M | 146.39M | 146.62M | 146.86M |
| Cash flow statement | ||||||||
| Operating cash flow | $422.42M | $454.63M | $554.13M | $339.75M | $457.32M | $538.77M | $578.66M | $308.62M |
| Capital expenditure | $48.74M | $51.13M | $33.65M | $28.54M | $42.97M | $30.59M | $20.80M | $20.64M |
| Free cash flow | $373.68M | $403.50M | $520.48M | $311.21M | $414.36M | $508.18M | $557.87M | $287.98M |
| Investing cash flow | $392.06M | -$383.65M | -$58.03M | -$50.94M | -$52.58M | -$133.71M | -$31.79M | -$36.69M |
| Financing cash flow | -$1.28B | -$263.16M | -$255.24M | -$258.35M | -$230.27M | -$163.89M | -$144.07M | -$147.54M |
| Depreciation & amortization | $41.74M | $44.78M | $58.98M | $49.88M | $47.70M | $63.63M | $43.67M | $46.44M |
| Stock-based compensation | $29.48M | $27.46M | $26.79M | $28.94M | $21.16M | $24.75M | $24.12M | $22.63M |
| Dividends paid | $94.95M | $87.09M | $87.24M | $87.58M | $87.75M | $77.59M | $77.70M | $77.69M |
| Share buybacks | $936.38M | $200.00M | $175.01M | $175.01M | $150.01M | $100.01M | $75.03M | $74.99M |
Free plan shows the latest 8 periods; Pro shows all 69 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.